Questcor: A Cheap Biotech Stock

Thursday, 17 Nov 2011 | 6:55 PM ET
Questcor: One-Drug Wonder
Questcor is a rare growth biotech, says Mad Money's Cramer, with a spectacular 42% growth rate, selling at 23 times earnings. Discussing the company's outlook, with Donald Bailey, Questcor Pharmaceuticals, Inc. CEO.

Questcor Pharmaceuticals is a rapidly growing biotech company with a terrific niche business, Cramer said Thursday.

“Questcor’s most recent quarter was spectacular, causing the stock to pop 20 percent on the news,” he said. “Even though the stock has run, it’s still cheap here on a growth basis, selling for 23 times earnings with a spectacular 42 percent growth rate.”

The company’s main product is an autoimmune drug chemical called Acthar Gel, but most of its sales come from combating three main diseases: multiple sclerosis relapses, infantile spasms and various kidney disorders.

To learn more about the company and where it’s headed, Cramer spoke with Questcor’s President and CEO Don Bailey. Watch the video to see the full interview.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

  Price   Change %Change


Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.